Valsgim 80 Agimexpharm treat hypertension, heart failure (2 blisters x 14 tablets)

Dosage form Box of 2 blisters x 14 tablets
Specifications Valsartan

Ingredient

Composition information	Content
Valsartan	80mg

Uses

indications

Valsgim 80 drugs are indicated to treat hypertension, heart failure for patients who do not respond to ACE inhibitors, reduce cardiovascular mortality on patients with left ventricular failure after myocardial infarction.

heart failure:

Treatment of heart failure (degree II - IV according to the classification of the New York Heart Association - NYHA) in patients who are being treated standard with diuretics, digitalis with or beta blockers or angiotensin transferring enzymes (ACE) but not using both; There is no mandatory all this standard treatment.

Valsgim improve the condition in these patients, starting through reducing hospitalization due to heart failure.

Vallsgim also slows down the progression of heart failure, improves the functional failure of NYHA's classification, increases the ability to pump blood, reduces the signs and symptoms of heart failure and improves the quality of life compared to the placebo.

after myocardial infarction:

Valsgim is indicated to improve the survival after myocardial infarction in clinical stable patients with signs, symptoms or existing X-rays of left ventricular failure and/or there is a left ventricular systolic dysfunction.

Pharmacology

Pharmacological group: Angiotensin II receptor anti -receptors

ATC code: C09CA03

Valsartan is an Angiotensin II type 1 receptor antagonist (AT1). Valsartan holds blood vessels not narrowing, lowering blood pressure and improving blood flow due to Valsartan prevents the physiological effects of Angiotensin II including vascular effects and secretion of aldosteron, by selecting Angiotensin II cohesion into the AT1 receptor in multiple tissues such as blood vessel muscles and adrenal glands.

When comparing, the enzyme inhibitors transferred Angiotensin (ACE, Kinase II) to prevent the conversion of angiotensin I into angiotensin II; However, the prevention of the formation of Angiotensin II by inhibiting ACE is not entirely because the hormone causes this vasoconstrictor can be formed through other enzymes that ACE inhibitors are not blocked.

Because Valsartan is not like the enzyme inhibitors, does not inhibit ACE, the drug does not hinder the response to Bradykinin and P; An effective result is that there is no side effects caused by ACE inhibitors (such as dry cough), but the effect on the kidneys and/or protect the heart may not be equal. Valsartan also does not interfere with the synthesis of angiotensin II.

The use of valsartan for hypertension patients leads to hypotension without affecting the heart rate.

On most patients, after taking a single dose, anti -hypertension effect is achieved within 2 hours and maximum hypotension is achieved within 4-6 hours. Anti -hypertension effect is maintained for more than 24 hours after taking the drug. In the process of repeating drugs, the maximum level of reducing blood pressure at any dose is achieved within 2-4 weeks and is maintained during the long -term treatment. If coordinated with hydrochlorothiazide, it is possible to achieve significant lower blood pressure.

The sudden stop use of Valsartan is not related to the sudden hypertension or clinical side effects.

In multi -dose studies in hypertension patients, Valsartan does not have the effects on total cholesterol, triglycerides when hungry, blood sugar when hungry, or uric acid.

pharmacokinetics

absorption:

Valsartan is quickly absorbed after drinking with birth about 23%. The peak concentration of Valsartan in plasma is reached 2-4 hours after a dose.

Distribution:

Valsartan is strongly connected to serum protein (94 - 97%), especially serum albumin.

Metabolism, elimination:

Valsartan is insignificant metabolized and excreted mainly through the honey in a constant form. The sale time is about 5 - 9 hours. After drinking, about 83% of the drug is eliminated in feces and 13% in the country.

Before taking Valsgim 80 Agimexpharm treat hypertension, heart failure (2 blisters x 14 tablets)

How to use

Valsgim 80 drugs are taken orally, regardless of meals.

Dosage

Hypertension:

Valsartan is used at the starting dose of 80 mg x 1 time/day.

Anti -hypertension effect is clearly shown within 2 weeks and the maximum effect reaches after 4 weeks. In patients with blood pressure is not controlled satisfactorily, daily bureaucracy may increase to 160 mg, or may add diuretics.

The starting dose is lower than 40 mg x 1 time/day for people over 75 years old, and people reduce the inner volume; Recommended reduction of dose on liver failure or kidney failure.

can also use Valsartan with other blood pressure mourning drugs.

heart failure:

Starting dose 40 mg x 2 times/day.

The highest dose is 80 mg - 160 mg x 2 times/day in patient tolerance.

It is necessary to consider reducing the dosage of diuretics simultaneously. The maximum dose/day used in clinical trials is 320 mg divided into several times.

When assessing patients with heart failure must always include kidney function assessment.

after myocardial infarction:

Valsartan may start early 12 hours after myocardial infarction in patients with stable clinical patients. The starting dose of 20 mg x 2 times/day, can be adjusted to 40 mg, 80 mg and 160mg x 2 times/day for the following weeks if tolerated. The maximum dose of 80 mg x 2 times/day is recommended for patients with liver failure.

If symptomic hypotension or kidney dysfunction occurs, the dose reduction should be considered.

Valsartan may be used in patients who have been treated with other medications after myocardial infarction, for example, the drug soluble thrombosis, acetylsalicylic acid, beta blockers or states.

When assessing patients with myocardial infarction must always include kidney function assessment.

Special subjects:

Hepatic failure or renal failure: No dose adjustment for patients with impaired renal function or patients with liver failure due to biliary tract and non -stasis.

Use in children and teenagers: The safety and effectiveness of Valsartan has not been identified in children and teenagers (under 18 years old).

Specific dose depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when using overdose? The most common overdose symptom is hypotension and tachycardia; It is also possible to occur slowly due to sympathetic nerve stimulation (vagus nerves). Reducing the level of awareness, circulation and shock were reported.

Handling: If you take a new medicine, you should cause vomiting. If hypotension occurs, the patient must be placed in a lying position and quickly added fluid and salt water. Valsartan is not able to be removed by dialysis.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

The harmful reactions are grouped by frequency: very common (ADR ≥ 1/10), common (1/100 ≤ ADR

usually light side effects. Can occur dizziness and dizziness when changing posture; Hypotension (HA), lower HA posture specially in patients with reduced intravascular volume (as patients who are taking high doses of gums).

Uncommon: Sometimes hyperkalemia occurs; There have been suitable reports for some Angiotensin II receptor blockers.

Rare: Rare cases such as anemia, neutropenia.

Very rare: diarrhea, taste disorders, fainting, fatigue, dry cough, headache, thrombocytopenia, nosebleeds, joint pain, muscle aches and sensitive reactions (such as mn, itching, vasculitis and serum disease).

Notify the physician with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

contraindicated valsgim in the following cases:

Hypersensitivity to other anti -Angiotensin II receiver and the ingredients of the drug.

Be cautious when using

Note to avoid alternative diet containing potassium.

Patients with sodium and/or epidemic loss:

In patients with sodium loss and/or severe epidemic loss such as high -dose treatment, rare hypotension, symptoms occur after the beginning of Valsartan.

Loss of sodium and/or epidemic loss should be treated before starting with valsartan treatment, for example reducing diuretics.

Patients with renal artery stenosis:

Use Valsartan in a short time for patients with secondary kidney hypertension due to the nest stenosis of the one side does not cause any significant changes in the kinetic hemodynamics in the kidneys, serum creatinine, or blood urea (bun).

However, because other drugs affect the renin-angiotensin-aldosteron system (RAAS) can increase serum blood urea and creatinine in patients with kidney stenosis on both sides or one side, so it is necessary to monitor as a safety measure.

Patients with kidney function:

No dose adjustment for patients with renal impairment. However, in severe cases (creatinine clearing coefficient

Patients with liver failure:

No dose adjustment for patients with liver failure. Valsartan is almost excreted in bile in a constant form, and patients with bile congestion show that the lower valsartan clearance. It is necessary to be careful when using Valsartan for patients with biliary congestion.

Patients with heart failure/myocardial infarction:

In patients with heart failure or after myocardial infarction, Valsartan is often lowered with blood pressure, no need to stop treating when hypotension if the dose is instructed as directed. Should be cautious when starting treatment in patients with heart failure.

The result of the inhibition of the renin-ankiotensin-aldosteron system, which changes the kidney function, depends on the sensitivity of each individual.

On patients with severe heart failure, their kidney function is likely to depend on the activity of the Renin-Anotensin-Aldosteron system, treated with angiotensin transfer inhibitors and Angiotensin receptor resistant can lead to urinary or hyperurgery and (rare) with acute renal failure and/or death.

When assessing patients with heart failure or after myocardial infarction, the kidney function must always be assessed.

In patients with heart failure, it is necessary to be cautious when combining three drugs including angiotensin transferring enzyme inhibitors, beta and valsartan blockers.

The effect of the drug on driving and operating machinery

No data mentioned about the effects of Valsartan on the ability to drive and operate machinery. When driving or operating machinery, it should be noted that occasionally dizziness or fatigue may occur during treatment with any hypertension.

Using drugs for women during pregnancy and lactation

Pregnancy:

Safety level when used for pregnant women: D (classification by FDA): Like drugs that directly affect the renin-angiotensin system, Valsartan is likely to cause damage and death for the fetus and infants when used for pregnant women. If you find pregnancy, you should stop using Valsartan as soon as possible. Need to apply firmly contraceptive methods when taking the drug.

Breastfeeding period:

It is unclear whether Valsartan is excreted through breast milk, but Valsartan is excreted through breastfeeding. Due to the ability to cause side effects in breastfeeding children, it is recommended to stop breastfeeding or stop taking the drug after considering the importance of the drug for the mother.

Interactive drug

Interaction of drugs with other drugs and other types of interactions:

There is no clinical interaction when Valsartan combines with cimetidin, warfarin, Furosemid, Digoxin, Atenolol, Indomethacin, Glibenclamid. The combination of Valsartan and Atenolol increases the anti -hypertension effect rather than used individually, but the effect of reducing heart rate is not equal to only using the single Atenolol alone. Combining Valsartan with Warfarin does not change Valsartan's pharmacokinetics or Warfarin's anticoagulant time.

Interacting with CYP 450: The enzyme is not responsible for transforming Valsartan but not the CYP 450 isozym.

Interacting with CYP 2C8/9: In Vitro testing tests related to recombinant CYP 450 enzymes indicate that isenzy CYP 2C9 is responsible for the formation of Valeryl-4-Hydroxy Valsartan, the first seaweed accounts for about 9% of the dose. Valsartan is weak with CYP 2C8, but there is no clinical report that has any meaning about this interaction.

Although Valsartan has the ability to connect high plasma proteins, in vitro studies have not shown any drug interactions at this concentration with a range of strong protein molecules such as DiClofenac, Furosemid, and Warfarin.

Concentrated with potassium diuretic (e.g. Spironolacton, triamteren, amilorid), potassium supplements, or replacement salts containing potassium can lead to increased serum potassium levels and in patients with heart failure, leading to increased serum creatinine. If simultaneous use of these drugs is necessary, it is necessary to monitor blood potassium.

The cavalry of the drug:

Due to the absence of studies on the correlation of the drug, not mixing this drug with other drugs.

Storage

Store at a temperature not exceeding 30 ° C in the original packaging, avoid moisture and avoid light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.